PBYI vs PFE
PBYI: Puma Biotechnology is an oncology-focused biopharmaceutical company commercializing the breast cancer drug NERLYNX and developing a pipeline of targeted therapies including the Aurora Kinase A inhibitor alisertib. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | PBYI | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $9.97 | $27.82 | |
| Market cap | $515M | $158.6B | |
| P/E as of 2026-10-08 | 20.90 | 36.83 | PBYI lower |
| Net margin FY2025, SEC XBRL | +13.6% | +12.4% | PBYI higher |
| Operating margin FY2025, SEC XBRL | +16.3% | n/a | |
| ROE FY2025, SEC XBRL | +23.9% | +9.0% | PBYI higher |
| ROA FY2025, SEC XBRL | +14.4% | +3.7% | PBYI higher |
| Debt / equity as of 2026-09-02 | 0.09 | 0.74 | PBYI lower |
| Revenue growth (YoY) as of 2026-09-02 | -2.4% | -0.2% | PFE higher |
| Revenue CAGR (3y) SEC XBRL | +0.0% | -14.8% | PBYI higher |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-02 | 0.71 | 0.39 | |
| 1-year return as of 2026-10-08 close | +90.6% | +8.3% | PBYI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.